<DOC>
	<DOCNO>NCT01754285</DOCNO>
	<brief_summary>This phase II , multicenter , double-blind , double-dummy , parallel-group , placebo-controlled , study evaluate LF-PB versus placebo female patient brest cancer undergo breast surgery axillary lymphnode dissection . Recruited patient randomly assign one follow treatment group : Placebo , LF-PB 10 mg , LF-PB 20 mg LF-PB 30 mg. Mode administration single intramuscular ( IM ) injection treatment arm follow : Placebo : 2 injection placebo LF-PB 10 mg : 2 injection = placebo + 10 mg LF-PB 20 mg : 2 injection = placebo + 20 mg LF-PB 30 mg : 2 injection = 10 mg + 20 mg The study randomize total 120 patient ( 30 per arm ) 10 Italian Sites .</brief_summary>
	<brief_title>Extended-release Octreotide ( LF-PB ) Treatment Lymphorrhea</brief_title>
	<detailed_description />
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Female age 18 80 year inclusive 2 . Body mass index ( BMI ) â‰¥18 kg/m2 3 . Signed informed consent form 4 . Diagnosis BC 5 . Undergoing breast surgery ALND Note : Collagen powder fibrin sealant permit . 6 . Negative serum pregnancy test woman childbearing potential Note : Female patient childbearing potential advise use adequate contraception necessary treatment octreotide . 7 . AST alanine aminotransferase ALT &lt; 1.5 x upper limit normal 8 . Ability fully understand study procedure comply study visit schedule duration study . 1 . Presence follow condition : 1 . Previous axillary surgery armpit undergo surgery study 2 . Previous chemotherapy radiotherapy within five year study drug administration 3 . Previous neoadjuvant therapy 4 . Recurrent BC breast undergoing surgery study 5 . Diabetes 6 . Cholelithiasis 7 . Hypothyroidism . If patient administer Euritox/ Levothyroxine ( analogue ) level T3 , T4 TSH confirm within normal range screen , patient enrol study . 8 . Hepatitis 9 . Pregnant lactate 10 . Human immunodeficiency virus hepatitis B C screen serology 2 . History radiotherapy breast armpit undergo surgery study . 3 . History anaphylaxis study drug 4 . Ascertained presumptive hypersensitivity active principle and/or ingredient study drug formulation 5 . QTc interval extension screen baseline &gt; 450 msec ( mean 3 consecutive reading 5 minute apart ) 6 . Presence disease use concomitant medication know increase QT interval ( see Appendix 2 list compound ) 7 . Clinically significant relevant abnormal medical history , vital sign , physical examination , ECG , laboratory evaluation find 8 . Current recurrent disease could affect result clinical laboratory assessment require study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>